JP4933455B2 - 新規のインスリン誘導体 - Google Patents

新規のインスリン誘導体 Download PDF

Info

Publication number
JP4933455B2
JP4933455B2 JP2007553601A JP2007553601A JP4933455B2 JP 4933455 B2 JP4933455 B2 JP 4933455B2 JP 2007553601 A JP2007553601 A JP 2007553601A JP 2007553601 A JP2007553601 A JP 2007553601A JP 4933455 B2 JP4933455 B2 JP 4933455B2
Authority
JP
Japan
Prior art keywords
tert
insulin
mmol
acid
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007553601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008528658A5 (enExample
JP2008528658A (ja
Inventor
コドラ、ヤノス・ティボル
ガリバイ、パトリック・ウィリアム
ホエグ−イェンセン、トマス
ヨナセン、イブ
マドセン、ペテル
タグモセ、ティナ・モルレル
Original Assignee
ノヴォ ノルディスク アー/エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノヴォ ノルディスク アー/エス filed Critical ノヴォ ノルディスク アー/エス
Publication of JP2008528658A publication Critical patent/JP2008528658A/ja
Publication of JP2008528658A5 publication Critical patent/JP2008528658A5/ja
Application granted granted Critical
Publication of JP4933455B2 publication Critical patent/JP4933455B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2007553601A 2005-02-02 2006-02-01 新規のインスリン誘導体 Expired - Fee Related JP4933455B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200500157 2005-02-02
DKPA200500157 2005-02-02
PCT/EP2006/050593 WO2006082204A1 (en) 2005-02-02 2006-02-01 Insulin derivatives

Publications (3)

Publication Number Publication Date
JP2008528658A JP2008528658A (ja) 2008-07-31
JP2008528658A5 JP2008528658A5 (enExample) 2012-02-09
JP4933455B2 true JP4933455B2 (ja) 2012-05-16

Family

ID=36096204

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007553601A Expired - Fee Related JP4933455B2 (ja) 2005-02-02 2006-02-01 新規のインスリン誘導体

Country Status (5)

Country Link
US (3) US8067362B2 (enExample)
EP (2) EP1846446B1 (enExample)
JP (1) JP4933455B2 (enExample)
ES (2) ES2428510T3 (enExample)
WO (1) WO2006082204A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660531A2 (en) * 2003-08-05 2006-05-31 Novo Nordisk A/S Novel insulin derivatives
JP2008507477A (ja) * 2004-07-08 2008-03-13 ノボ ノルディスク アクティーゼルスカブ ポリペプチド延長タグ
US8067362B2 (en) 2005-02-02 2011-11-29 Novo Nordisk As Insulin derivatives
DK1969004T3 (da) 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
AU2007247109B2 (en) * 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
ES2553154T3 (es) * 2006-05-09 2015-12-04 Novo Nordisk A/S Derivado de la insulina
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
ES2601839T3 (es) 2006-09-22 2017-02-16 Novo Nordisk A/S Análogos de insulina resistentes a proteasas
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
ES2526924T3 (es) * 2007-08-15 2015-01-16 Novo Nordisk A/S Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol
WO2009022005A1 (en) * 2007-08-15 2009-02-19 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
EP2058330A1 (en) * 2007-11-08 2009-05-13 Novo Nordisk A/S Insulin derivative
JP5715418B2 (ja) * 2007-11-08 2015-05-07 ノボ・ノルデイスク・エー/エス インスリン誘導体
JP5762001B2 (ja) 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー/エス プロテアーゼ安定化インスリンアナログ
EP2910571B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
CA2784757A1 (en) * 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives
HRP20191793T1 (hr) 2010-10-27 2019-12-27 Novo Nordisk A/S Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja
CN103209711B (zh) 2010-11-09 2016-04-13 诺沃—诺迪斯克有限公司 双-酰化的glp-1衍生物
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
PT2696687T (pt) 2011-04-12 2017-02-02 Novo Nordisk As Derivados de glp-1 duplamente acilados
EP2720711A1 (en) 2011-06-15 2014-04-23 Novo Nordisk A/S Multi substituted insulins
WO2013037690A1 (en) 2011-09-06 2013-03-21 Novo Nordisk A/S Glp-1 derivatives
EP2820038B1 (en) 2012-03-01 2020-06-17 Novo Nordisk A/S Glp-1 prodrugs
LT2827885T (lt) 2012-03-22 2018-10-10 Novo Nordisk A/S Glp-1 peptidų kompozicijos ir jų gavimas
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
ES2629735T3 (es) 2012-05-08 2017-08-14 Novo Nordisk A/S Derivados de GLP-1 doblemente acilados
EP2863895B1 (en) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
EP4406597A3 (en) 2013-03-13 2024-11-13 onCOUR Pharma, Inc. Immune-modifying particles for the treatment of inflammation
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
HRP20181393T1 (hr) 2013-05-02 2018-11-02 Novo Nordisk A/S Oralno doziranje spojeva glp-1
FI3033102T4 (fi) 2013-08-13 2024-03-01 Univ Northwestern Peptidikonjugoituja hiukkasia
MX366636B (es) 2013-10-07 2019-07-17 Novo Nordisk As Nuevo derivado de un análogo de insulina.
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
US11510996B2 (en) 2015-12-23 2022-11-29 Cour Pharmaceuticals Development Company Inc. Covalent polymer-antigen conjugated particles
CA3046583A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions
CN110945017B (zh) 2017-07-19 2024-07-16 诺和诺德股份有限公司 双功能化合物
US10919949B2 (en) 2017-08-17 2021-02-16 Novo Nordisk A/S Acylated insulin analogues and uses thereof
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
MX2021006972A (es) 2018-12-11 2021-08-16 Sanofi Sa Conjugados de insulina.
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
CN114306577B (zh) * 2020-10-10 2024-04-09 南京汉欣医药科技有限公司 一种门冬胰岛素30混悬液的制备方法
CN116283636A (zh) * 2023-01-16 2023-06-23 安徽盈科生物科技有限公司 德谷胰岛素侧链合成的方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB894095A (en) 1960-02-08 1962-04-18 Tanaka Shoichi A therapeutic device for personal wear
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ ノルディスク アクティーゼルスカブ ヒトインシュリン類似物質
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
DK45590D0 (enExample) 1990-02-21 1990-02-21 Novo Nordisk As
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
DK0792290T3 (da) 1993-09-17 2001-10-01 Novo Nordisk As Acyleret insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
EP0871665B1 (en) 1995-03-17 2003-07-23 Novo Nordisk A/S Insulin derivatives
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
CZ220498A3 (cs) 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
PT938502E (pt) 1996-07-11 2005-02-28 Novo Nordisk As Metodo selectivo por acilacao
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
PT944648E (pt) 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
BR9810378A (pt) 1997-07-01 2000-08-29 Novo Nordisk As Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
CA2294830A1 (en) 1997-07-16 1999-01-28 John Bondo Hansen Fused 1,2,4-thiadiazine derivatives, their preparation and use
AU1870099A (en) 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
JPH11254699A (ja) 1998-03-09 1999-09-21 Brother Ind Ltd 画像記録装置
ES2200575T3 (es) 1998-12-18 2004-03-01 Novo Nordisk A/S Derivados de 1,2,4-tiadiazina fusionados, su preparacion y uso.
EP1147094A1 (en) 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
CA2447236A1 (en) 2001-05-21 2002-11-28 Nektar Therapeutics Pulmonary administration of chemically modified insulin
JP2004537580A (ja) 2001-08-10 2004-12-16 エピックス メディカル, インコーポレイテッド 延長された循環半減期を有するポリペプチド結合体
AU2003208316A1 (en) 2002-03-13 2003-09-22 Novo Nordisk A/S Minimising body weight gain in insulin treatment
WO2005005477A2 (en) 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
EP1660531A2 (en) 2003-08-05 2006-05-31 Novo Nordisk A/S Novel insulin derivatives
JP2007532096A (ja) 2003-11-14 2007-11-15 ノボ ノルディスク アクティーゼルスカブ アシル化されたインスリンの製造方法
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
US8067362B2 (en) * 2005-02-02 2011-11-29 Novo Nordisk As Insulin derivatives
ES2435522T3 (es) 2005-02-02 2013-12-20 Novo Nordisk A/S Derivados de insulina
DK1969004T3 (da) 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
ES2553154T3 (es) 2006-05-09 2015-12-04 Novo Nordisk A/S Derivado de la insulina
AU2007247109B2 (en) 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
JP5715418B2 (ja) 2007-11-08 2015-05-07 ノボ・ノルデイスク・エー/エス インスリン誘導体
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
ES2612468T3 (es) 2010-05-10 2017-05-17 Novo Nordisk A/S Procedimiento para la preparación de complejos de insulina-zinc

Also Published As

Publication number Publication date
EP2256130A1 (en) 2010-12-01
WO2006082204A1 (en) 2006-08-10
ES2428510T3 (es) 2013-11-08
USRE46170E1 (en) 2016-10-04
US8067362B2 (en) 2011-11-29
ES2438145T3 (es) 2014-01-16
EP2256130B1 (en) 2013-09-25
JP2008528658A (ja) 2008-07-31
US20120035104A1 (en) 2012-02-09
EP1846446A1 (en) 2007-10-24
US8476228B2 (en) 2013-07-02
EP1846446B1 (en) 2013-06-26
US20080076705A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
JP4933455B2 (ja) 新規のインスリン誘導体
EP2107069B1 (en) Novel insulin derivatives
RU2164520C2 (ru) Производное инсулина, растворимая пролонгированная фармацевтическая композиция, способ пролонгирования гипогликемического действия при лечении диабета
US20250032589A1 (en) Insulin Derivative
US6869930B1 (en) Acylated insulin
JP5269766B2 (ja) インスリン誘導体
EP2275439B1 (en) Novel insulin derivatives
US20140328943A1 (en) Insulin compositions and method of making a composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111206

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20111216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120117

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120216

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150224

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees